Hong Kong Pharmaceuticals Stock News

SEHK:636
SEHK:636Logistics

Is KLN Logistics Group (SEHK:636) Now Offering Value After Multi Year Share Price Weakness

This article examines whether KLN Logistics Group at HK$6.65 could be a potential bargain or a value trap, and walks through key signals to help you frame that question clearly. The stock has recently been under pressure, with returns of 1.8% over 7 days, 4.9% over 30 days, 7.9% year to date and 0.8% over the past year, alongside declines of 39.0% and 50.4% across 3 and 5 years respectively. Recent attention around KLN Logistics Group has focused less on short term headlines and more on how...
SEHK:9992
SEHK:9992Specialty Retail

Is Pop Mart International Group (SEHK:9992) Price Justified After Its Strong Multi‑Year Share Surge?

Many investors are considering whether Pop Mart International Group shares still represent good value after a strong run, or whether the price has already moved ahead of the fundamentals. The stock last closed at HK$217.2, with returns of 0.8% over 7 days, an 11.1% decline over 30 days, 12.5% year to date and 71.9% over 1 year, along with a very large 3-year return. Recent attention has focused on how Pop Mart fits into consumer trends in collectibles and branded merchandise, with investors...
SEHK:3918
SEHK:3918Hospitality

NagaCorp (SEHK:3918) Net Margin Surge Tests Single Market Risk Narratives

NagaCorp (SEHK:3918) has put up a solid set of FY 2025 numbers, with first half revenue of US$320.6 million and basic EPS of US$0.0336, set against reported earnings growth of 182.8% year over year and a five year compound growth rate of 45.7% per year. The company has seen revenue move from US$252.9 million in the second half of 2024 to US$320.6 million in the first half of 2025, while basic EPS shifted from US$0.0250 to US$0.0336 over the same periods. Investors will be weighing these...
SEHK:386
SEHK:386Oil and Gas

Is It Time To Reassess Sinopec (SEHK:386) After The Recent Share Price Pullback?

Wondering whether China Petroleum & Chemical at HK$4.53 still offers value, or if the easy gains are behind it? This article walks through what the current price really reflects. The stock has seen a 5.0% decline over the last 7 days and a 16.3% decline over the last 30 days, yet it shows returns of 15.5% over 1 year, 23.5% over 3 years and 67.3% over 5 years. Recent market conversations around China Petroleum & Chemical have focused on how its share price performance lines up with broader...
SEHK:6990
SEHK:6990Biotechs

Is It Time To Reassess Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) After Recent Share Price Weakness?

Wondering whether Sichuan Kelun-Biotech Biopharmaceutical is still priced attractively, or if the easy value has already been taken? This breakdown focuses squarely on what you are paying versus what you are getting. The share price recently closed at HK$397.60, after a 4.4% decline over the last week and a 4.6% decline over the past month, while the 1 year return sits at 52.6%. Recent news coverage has focused on Sichuan Kelun-Biotech Biopharmaceutical in the context of investor interest in...
SEHK:6862
SEHK:6862Hospitality

Is Haidilao International Holding (SEHK:6862) Attractive After Mixed Price Moves And DCF Upside?

Wondering if Haidilao International Holding at HK$15.85 is a bargain or a value trap? This article breaks down what the current price might actually reflect. The stock has had a mixed run, with a 10% year-to-date gain alongside 1% and 6% declines over the past 7 days and 30 days, and a 2.6% decline over the last year plus a 64.6% decline over five years that many investors still have in mind. Recent coverage has focused on Haidilao International Holding as a Hong Kong listed consumer...
SEHK:2869
SEHK:2869Real Estate

Greentown Service Group SEHK 2869 Margin Gain Questions Cautious Growth Narratives

Greentown Service Group (SEHK:2869) has put fresh numbers on the board for FY 2025, with first half revenue of about C¥9.3b and basic EPS of C¥0.19 setting the tone for its latest earnings update. The company has seen first half revenue move from C¥8.2b in 2023 to C¥8.8b in 2024 and then to C¥9.3b in 2025. Over the same periods, basic EPS shifted from C¥0.13 to C¥0.16 and then to C¥0.19, giving a clear view of how the top and bottom line have tracked together. For investors, the current...
SEHK:866
SEHK:866Oil and Gas

A Look At China Qinfa Group (SEHK:866) Valuation After Its Recent Follow On Equity Offering

China Qinfa Group (SEHK:866) has completed a follow on equity offering and raised HK$315.9 million through a subsequent direct listing of 90,000,000 new ordinary shares at HK$3.51 each, expanding its share capital base. See our latest analysis for China Qinfa Group. At a share price of HK$3.94, China Qinfa Group has seen a 10.67% one-month share price return and a roughly 18x one-year total shareholder return, with momentum building over the past quarter as investors react to the capital...
SEHK:6963
SEHK:6963Insurance

A Look At Sunshine Insurance Group (SEHK:6963) Valuation After Annual Results And Final Dividend Proposal

Sunshine Insurance Group (SEHK:6963) just released its full year 2025 results alongside a proposed final cash dividend of RMB 0.19 per ordinary share, a pairing that gives investors fresh income and earnings context. See our latest analysis for Sunshine Insurance Group. The latest HK$3.71 share price comes after a 1-day share price return of 0.54%, with the dividend and earnings announcement likely shaping how investors view Sunshine Insurance Group's risk and income profile. Despite a 30-day...
SEHK:2377
SEHK:2377Commercial Services

China Boqi Environmental (SEHK:2377) Margin Improvement Challenges Long‑Term Earnings Drift Narrative

China Boqi Environmental (Holding) (SEHK:2377) has posted its FY 2025 first half numbers with revenue of C¥1,058.5 million and basic EPS of C¥0.166, against trailing twelve month revenue of C¥2,260.0 million and EPS of C¥0.285 that sit alongside a 20.6% uplift in earnings and an 11.7% net margin over the last year. The company has seen revenue move from C¥949.4 million in 1H FY 2024 to C¥1,058.5 million in 1H FY 2025, while basic EPS moved from C¥0.114 to C¥0.166 over the same halves. This...
SEHK:2567
SEHK:2567Software

Qiniu (SEHK:2567) Loss Narrows To C¥33.4m Challenging Persistent Bearish Narratives

Qiniu (SEHK:2567) has opened FY 2025 with first half revenue of C¥829.4 million and a basic EPS loss of C¥0.02 per share, alongside a net income loss of C¥33.4 million. This sets a cautious tone for investors watching the company’s path toward profitability. The company has seen first half revenue move from C¥710.4 million in FY 2024 to C¥829.4 million in FY 2025, while basic EPS shifted from a loss of C¥0.41 to a smaller loss of C¥0.02. This frames a set of results where revenue scale and...
SEHK:257
SEHK:257Commercial Services

Everbright Environment Group SEHK 257 Margin Improvement Challenges Longstanding Bearish Earnings Narrative

China Everbright Environment Group (SEHK:257) has just posted its FY 2025 first half numbers, reporting revenue of HK$14.3b and net income of HK$2.2b, equivalent to basic EPS of HK$0.36, alongside year over year earnings growth of 16.2%. The company has seen revenue move from HK$15.6b in 1H 2024 to HK$14.3b in 1H 2025 while basic EPS shifted from HK$0.40 to HK$0.36 over the same period. This sets the backdrop for a current net profit margin of 14.3% compared with 11.2% a year earlier. For...
SEHK:3613
SEHK:3613Pharmaceuticals

Beijing Tong Ren Tang Chinese Medicine (SEHK:3613) Margin Compression Challenges Bullish Quality Narrative

How Beijing Tong Ren Tang Chinese Medicine's FY 2025 Numbers Set Up the Next Chapter Beijing Tong Ren Tang Chinese Medicine (SEHK:3613) has just posted FY 2025 first half numbers, with revenue of HK$761.7 million and basic EPS of HK$0.28, setting the tone for how investors will read the rest of the year. Over the last three reported halves, revenue has moved from HK$664.5 million in 1H 2024 to HK$947.1 million in 2H 2024 and now HK$761.7 million in 1H 2025, while basic EPS has tracked...
SEHK:570
SEHK:570Pharmaceuticals

China Traditional Chinese Medicine (SEHK:570) Half Year Loss Challenges Turnaround Narrative

China Traditional Chinese Medicine Holdings (SEHK:570) has reported its FY 2025 first half results with revenue of C¥7.5b and a basic EPS loss of C¥0.02, while the trailing twelve months show revenue of C¥14.7b and a basic EPS loss of C¥0.07. Over recent half year periods, revenue has moved from C¥8.4b with EPS of C¥0.04 in 1H 2024 to C¥8.1b with an EPS loss of C¥0.03 in 2H 2024, then to C¥7.5b with an EPS loss of C¥0.02 in 1H 2025, setting up a story where investors are weighing weaker...